Vertex Pharmaceuticals said on Tuesday its next-generation cystic fibrosis treatment has won European Union approval for a ...

Cystic fibrosis (CF) is a rare autosomal recessive disorder that affects numerous systems of the body. It is a complicated ...

ECMO use in cystic fibrosis with severe respiratory failure showed limited survival, highlighting the need for cautious ...

With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis ...

At 7 years old, Morgan Barrett was diagnosed with cystic fibrosis. Prior to her diagnosis, she struggled to gain weight ...

The prevalence of food allergy is significantly lower in children with cystic fibrosis than in those without the condition in ...

Chronic colonization by filamentous fungi in patients with cystic fibrosis (pwCF) is linked to declines in lung function and quality of life. To better assess indoor mold exposure, 23 French dwellings ...

North Carolina man created a foundation to help other patients navigate expenses of an unexpectedly longer life ...

Most children with CF treated at a San Francisco CF clinic did not receive CF liver disease screening in accordance with current guidelines.

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK® ...

Affordable access to life-changing treatment for cystic fibrosis will be expanded to more Australians with a change to the ...

VRTX secures EU approval for Alyftrek, a next-in-class triple combination regimen for treating people with CF aged six years ...